174 related articles for article (PubMed ID: 36921738)
1. Co-targeting of ACK1 and KIT triggers additive anti-proliferative and -migration effects in imatinib-resistant gastrointestinal stromal tumors.
He W; Xu L; Ding J; Song L; Yang W; Klooster I; Pilco-Janeta DF; Serrano C; Fang H; Jiang G; Wang X; Yu J; Ou WB
Biochim Biophys Acta Mol Basis Dis; 2023 Jun; 1869(5):166690. PubMed ID: 36921738
[TBL] [Abstract][Full Text] [Related]
2. Coordinated targeting of CK2 and KIT in gastrointestinal stromal tumours.
Huang M; Yang W; Zhu J; Mariño-Enríquez A; Zhu C; Chen J; Wu Y; Quan Y; Qiu H; Li X; Chai L; Fletcher JA; Ou WB
Br J Cancer; 2020 Feb; 122(3):372-381. PubMed ID: 31776458
[TBL] [Abstract][Full Text] [Related]
3. Dual Targeting of Insulin Receptor and KIT in Imatinib-Resistant Gastrointestinal Stromal Tumors.
Chen W; Kuang Y; Qiu HB; Cao Z; Tu Y; Sheng Q; Eilers G; He Q; Li HL; Zhu M; Wang Y; Zhang R; Wu Y; Meng F; Fletcher JA; Ou WB
Cancer Res; 2017 Sep; 77(18):5107-5117. PubMed ID: 28760855
[TBL] [Abstract][Full Text] [Related]
4. A Novel Receptor Tyrosine Kinase Switch Promotes Gastrointestinal Stromal Tumor Drug Resistance.
Boichuk S; Galembikova A; Dunaev P; Valeeva E; Shagimardanova E; Gusev O; Khaiboullina S
Molecules; 2017 Dec; 22(12):. PubMed ID: 29206199
[TBL] [Abstract][Full Text] [Related]
5. Frequent mono-allelic loss associated with deficient PTEN expression in imatinib-resistant gastrointestinal stromal tumors.
Quattrone A; Wozniak A; Dewaele B; Floris G; Vanspauwen V; Van Looy T; Schöffski P; Rutkowski P; Sciot R; Debiec-Rychter M
Mod Pathol; 2014 Nov; 27(11):1510-20. PubMed ID: 24743220
[TBL] [Abstract][Full Text] [Related]
6. PI3K/AKT/mTOR pathway is activated after imatinib secondary resistance in gastrointestinal stromal tumors (GISTs).
Li J; Dang Y; Gao J; Li Y; Zou J; Shen L
Med Oncol; 2015 Apr; 32(4):111. PubMed ID: 25757539
[TBL] [Abstract][Full Text] [Related]
7. Bromodomain and extraterminal domain inhibitor enhances the antitumor effect of imatinib in gastrointestinal stromal tumours.
Mu J; Sun P; Ma Z; Sun P
J Cell Mol Med; 2020 Feb; 24(4):2519-2530. PubMed ID: 31957165
[TBL] [Abstract][Full Text] [Related]
8. KIT over-expression by p55PIK-PI3K leads to Imatinib-resistance in patients with gastrointestinal stromal tumors.
Lai S; Wang G; Cao X; Luo X; Wang G; Xia X; Hu J; Wang J
Oncotarget; 2016 Jan; 7(2):1367-79. PubMed ID: 26587973
[TBL] [Abstract][Full Text] [Related]
9. Nuclear KIT induces a NFKBIB-RELA-KIT autoregulatory loop in imatinib-resistant gastrointestinal stromal tumors.
Hsueh YS; Chang HH; Shan YS; Sun HS; Fletcher JA; Li CF; Chen LT
Oncogene; 2019 Sep; 38(38):6550-6565. PubMed ID: 31363162
[TBL] [Abstract][Full Text] [Related]
10. Silencing of adaptor protein SH3BP2 reduces KIT/PDGFRA receptors expression and impairs gastrointestinal stromal tumors growth.
Serrano-Candelas E; Ainsua-Enrich E; Navinés-Ferrer A; Rodrigues P; García-Valverde A; Bazzocco S; Macaya I; Arribas J; Serrano C; Sayós J; Arango D; Martin M
Mol Oncol; 2018 Aug; 12(8):1383-1397. PubMed ID: 29885053
[TBL] [Abstract][Full Text] [Related]
11. SOCS1 gene therapy has antitumor effects in imatinib-resistant gastrointestinal stromal tumor cells through FAK/PI3 K signaling.
Sugase T; Takahashi T; Serada S; Fujimoto M; Ohkawara T; Hiramatsu K; Nishida T; Hirota S; Saito Y; Tanaka K; Miyazaki Y; Makino T; Kurokawa Y; Yamasaki M; Nakajima K; Hanasaki K; Kishimoto T; Mori M; Doki Y; Naka T
Gastric Cancer; 2018 Nov; 21(6):968-976. PubMed ID: 29623544
[TBL] [Abstract][Full Text] [Related]
12. Cas-L was overexpressed in imatinib-resistant gastrointestinal stromal tumor cells.
Thao le B; Vu HA; Yasuda K; Taniguchi S; Yagasaki F; Taguchi T; Watanabe T; Sato Y
Cancer Biol Ther; 2009 Apr; 8(8):683-8. PubMed ID: 19417561
[TBL] [Abstract][Full Text] [Related]
13. KIT and BRAF heterogeneous mutations in gastrointestinal stromal tumors after secondary imatinib resistance.
Zheng S; Huang KE; Pan YL; Zhou Y; Pan SD; Li X; Jia J; Zheng XL; Tao DY
Gastric Cancer; 2015 Oct; 18(4):796-802. PubMed ID: 25182956
[TBL] [Abstract][Full Text] [Related]
14. Combination of Imatinib Mesylate and AKT Inhibitor Provides Synergistic Effects in Preclinical Study of Gastrointestinal Stromal Tumor.
Zook P; Pathak HB; Belinsky MG; Gersz L; Devarajan K; Zhou Y; Godwin AK; von Mehren M; Rink L
Clin Cancer Res; 2017 Jan; 23(1):171-180. PubMed ID: 27370604
[TBL] [Abstract][Full Text] [Related]
15. Preclinical Activity of PI3K Inhibitor Copanlisib in Gastrointestinal Stromal Tumor.
García-Valverde A; Rosell J; Serna G; Valverde C; Carles J; Nuciforo P; Fletcher JA; Arribas J; Politz O; Serrano C
Mol Cancer Ther; 2020 Jun; 19(6):1289-1297. PubMed ID: 32371592
[TBL] [Abstract][Full Text] [Related]
16. Mesenchymal stromal cells promote the drug resistance of gastrointestinal stromal tumors by activating the PI3K-AKT pathway via TGF-β2.
Zhao Y; Weng Z; Zhou X; Xu Z; Cao B; Wang B; Li J
J Transl Med; 2023 Mar; 21(1):219. PubMed ID: 36966336
[TBL] [Abstract][Full Text] [Related]
17. Platelet-Derived Growth Factor Receptor-α Regulates Proliferation of Gastrointestinal Stromal Tumor Cells With Mutations in KIT by Stabilizing ETV1.
Hayashi Y; Bardsley MR; Toyomasu Y; Milosavljevic S; Gajdos GB; Choi KM; Reid-Lombardo KM; Kendrick ML; Bingener-Casey J; Tang CM; Sicklick JK; Gibbons SJ; Farrugia G; Taguchi T; Gupta A; Rubin BP; Fletcher JA; Ramachandran A; Ordog T
Gastroenterology; 2015 Aug; 149(2):420-32.e16. PubMed ID: 25865047
[TBL] [Abstract][Full Text] [Related]
18. KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway.
Bauer S; Duensing A; Demetri GD; Fletcher JA
Oncogene; 2007 Nov; 26(54):7560-8. PubMed ID: 17546049
[TBL] [Abstract][Full Text] [Related]
19. Protein kinase C-theta regulates KIT expression and proliferation in gastrointestinal stromal tumors.
Ou WB; Zhu MJ; Demetri GD; Fletcher CD; Fletcher JA
Oncogene; 2008 Sep; 27(42):5624-34. PubMed ID: 18521081
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanisms of secondary imatinib resistance in patients with gastrointestinal stromal tumors.
Wang CM; Huang K; Zhou Y; Du CY; Ye YW; Fu H; Zhou XY; Shi YQ
J Cancer Res Clin Oncol; 2010 Jul; 136(7):1065-71. PubMed ID: 20043176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]